24/7 Market News Snapshot 18 September, 2024 – Immunic, Inc. Common Stock (NASDAQ:IMUX)

September 18, 2024

DENVER, Colo., 18 September, 2024 (247marketnews.com) – (NASDAQ:IMUX) are discussed in this article.
Immunic, Inc. (IMUX) has recently captured significant attention in the financial markets following impressive stock performance and promising clinical research findings. The company’s share price opened at $1.68 and surged by 23.23% to reach $1.984, indicating a notable increase from the previous close of $1.610. With a trading volume exceeding 1.04 million shares, this upward movement reflects a surge of investor interest in Immunic, suggesting favorable prospects associated with its innovative drug development.

At the forefront of this optimism is the recent presentation of critical clinical data regarding the company’s lead candidate, vidofludimus calcium (IMU-838), during the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The interim analysis from the Phase 2 CALLIPER trial revealed a significant 22.4% reduction in neurofilament light chain (NfL) levels—an important biomarker for neurodegeneration—among the 203 patients receiving vidofludimus calcium compared to those on placebo. This effect was consistent across diverse patient demographics, highlighting the drug’s potential in treating progressive multiple sclerosis.

In addition to its applications for multiple sclerosis, emerging findings suggest vidofludimus calcium may provide benefits for patients suffering from post-COVID fatigue, potentially due to its antiviral properties. Data indicated that only 50% of those treated with vidofludimus calcium reported fatigue, significantly lower than the placebo group.

Immunic’s Chief Executive Officer, Daniel Vitt, Ph.D., emphasized the importance of these findings, reinforcing the company’s goal to advance vidofludimus calcium as a transformative treatment option for multiple sclerosis and related conditions. With further data anticipated in April, Immunic remains on a trajectory poised for substantial advancements in the treatment landscape for neurodegenerative diseases.

Related news for (IMUX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.